Institut De Cancerologie Strasbourg Europe

The medical center is at the forefront of research in metastatic castration-resistant prostate cancer, focusing on innovative treatments like ODM-208. This research aims to enhance the understanding of androgen receptor mutations and their impact on treatment efficacy.

• Safety and pharmacokinetics of ODM-208
• Antitumor activity in mutated androgen receptor domains
• Drug-drug interaction potential with CYP3A4

These studies contribute significantly to the development of personalized therapies for prostate cancer patients.

Our center is pioneering research in metastatic urothelial cancer, evaluating the efficacy of sacituzumab govitecan compared to traditional treatments. This work is crucial in improving survival rates and quality of life for patients with advanced stages of the disease.

• Overall survival assessment with sacituzumab govitecan
• Comparison with physician's choice treatments

These efforts are paving the way for more effective therapeutic options in urothelial cancer management.

The center is advancing research in ER-positive, HER2-negative breast cancer, exploring the combination of durvalumab, olaparib, and fulvestrant. This study focuses on genetic alterations such as BRCA mutations and their role in treatment response.

• Efficacy of combination therapies
• Progression-free survival rates
• Genetic markers in treatment response

Our research is instrumental in developing targeted therapies for breast cancer patients with specific genetic profiles.

Our institution is leading studies on advanced sarcomas, particularly rare subtypes, by comparing nivolumab and ipilimumab with pazopanib. This research aims to improve progression-free survival and treatment outcomes for these challenging cases.

• Comparative efficacy of immunotherapy combinations
• Progression-free survival in rare sarcomas

These studies are crucial in enhancing therapeutic strategies for patients with rare and aggressive sarcoma types.

The center is conducting pivotal research in renal cell carcinoma, focusing on the combination of tivozanib and nivolumab. This study aims to improve progression-free survival and overall treatment efficacy for patients who have undergone previous therapies.

• Combination therapy efficacy
• Progression-free survival improvements

Our research is contributing to the development of more effective treatment regimens for renal cell carcinoma.

Our center is at the forefront of research in metastatic endometrial and ovarian carcinosarcoma, evaluating the efficacy of dostarlimab and niraparib. This study is crucial in identifying optimal treatment strategies for these aggressive cancers.

• Combination therapy efficacy
• Selection of optimal treatment strategies

These efforts are vital in advancing therapeutic options for patients with challenging gynecological cancers.